BPC-157 in Interstitial Cystitis: A 12-Patient Pilot Study
This private-clinic pilot described symptom reports after a single procedure involving BPC-157 in 12 women with interstitial cystitis who had not responded to pentosan polysulfate.
Study design
Participants underwent cystoscopy and injections around areas of bladder inflammation. The investigators used a Global Response Assessment questionnaire after treatment; there was no placebo or comparator group.
What the researchers reported
Ten participants reported complete symptom resolution and two reported substantial but incomplete resolution. The abstract reported no dropouts or adverse events in this small cohort.
What this result does not establish
An uncontrolled 12-person pilot cannot separate treatment effects from placebo response, procedural effects, selection bias or measurement bias. It does not establish efficacy or general safety.
This article summarizes one published study about BPC-157. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.
Related research material
Review the corresponding catalogue listing, labelled amount and available documentation. The study may use a different formulation or experimental preparation; it does not verify our product, its batch or suitability for human use.
Our Approach
Evidence before assumption.
TAM Global Research focuses on transparent documentation, careful scientific interpretation and clear distinction between what available evidence supports and what requires further verification.
Explore our quality standards